Areas of work

Below are a few links to pages that show our work in specific fields (note: this list is currently under construction and will be continually updated):

• Innovation and access to medical technologies
  • Cancer Drugs
  • Coronavirus/COVID-19
  • Orphan/Rare diseases
  • A standalone page on delinking R&D costs from product prices: Delinkage.org
  • U.S. Government-Funded Inventions
    • Bayh-Dole Act
    • Licensing of NIH-owned patents
    • Licensing by U.S. government agencies, other than NIH
    • Litigation: KEI v. NIH et al.
    • March-in and royalty-free rights under Bayh-Dole
    • Failures to disclose U.S. government rights in patents.
  • CAR T-cell Technologies
  • CRISPR
• Compulsory licensing of patents
• • Global norms on compulsory licensing
  • Country experiences
  • 28 USC 1498
  • Compulsory licensing in the context of U.S. injunction cases involving medical technologies
  • Compulsory licensing in the context of U.S. injunction cases involving non-medical technologies
• Multilateral Negotiations
  • World Trade Organization (WTO)
  • Hague Conference
  • United Nations
    • WHO
    • WIPO
      • WIPO Development Agenda
      • WIPO SCCR
      • WIPO SCP
      • WIPO Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore
      • WIPO Broadcasters Treaty
      • Marrakesh Treaty for the blind
• Access to Knowledge
  • Copyright
    • Copyright exceptions
    • Term of copyright and related rights
    • Orphan Works
    • Right to Read for Persons with Reading Disabilities
  • Open Access
  • Open source / Free Software
  • Transparency
• Trade policy including plurilateral negotiations
  • USTR’s Special 301 list
  • ACTA
  • TPP
  • TTIP
  • TISA
  • RCEP
• Competition Policy
• New models of funding the supply of knowledge and other goods
  • Proposal for a WTO agreement on the supply of public goods
  • Proposals for global agreements on research and development
  • The Blur-Banff Proposal
  • Proposals for delinking R&D costs from prices of medical products and service.
• Evidence, data, History
  • R&D Costs for specific drugs
  • Research on the Orphan Drug Tax Credit
  • KEI Timelines
• Nuclear Proliferation